Uses of 2-phenyl-substituted imidazotriazinone derivatives...

Details Uses of 2-phenyl-substituted imidazotriazinone derivatives... Uses of 2-phenyl-substituted imidazotriazinone derivatives...

A - Human Necessities

61

K

A61K 31/53 (2006.01) A61P 11/06 (2006.01) A61P 11/08 (2006.01)

Patent

CA 2603935

The invention relates to the use of PDE 5 inhibitors in general and especially of known 2-phenyl-substituted imidazotriazinone derivatives, such as e.g. Vardenafil, for producing drugs used in the treatment of clinical pictures that can be treated by increasing the cGMP levels in certain tissues, for example of diseases such as primary pulmonary hypertension, secondary pulmonary hypertension, pulmonary arterial hypertension, portopulmonary hypertension, hepatopulmonary syndrome, pulmonary hypertension caused by drugs (amphetamines), interstitial lung disease, HIV-related pulmonary hypertension, thromboembolic pulmonary hypertension, pulmonary hypertension in children and newborn children, atmospheric hypoxia-induced pulmonary hypertension (mountain sickness), COPD, emphysema, chronic bronchial asthma, cystic fibrosis-related pulmonary hypertension, right ventricular failure, left ventricular failure and global failure, and that can be treated by increasing the cGMP levels in certain tissues, such as for example isolated systolic hypertension (ISH) and vascular sclerosis, in particular arterial blood vessels. The invention also relates to the combinations of PDE 5 inhibitors in general and especially of known 2-phenyl-substituted imidazotriazinone derivatives with additional therapeutic agents for the indications mentioned above.

La présente invention concerne l'utilisation d'inhibiteurs de PDE 5, en particulier de dérivés d'imidazotriazinone 2-phényl-substitués connus, par exemple du vardénafil, pour produire des médicaments permettant de traiter des syndromes qui peuvent être traités en augmentant les taux de cGMP dans des tissus définis, par exemple une hypertension pulmonaire primaire, une hypertension pulmonaire secondaire, une hypertension artérielle pulmonaire, une hypertension portopulmonaire, un syndrome hépatopulmonaire, une hypertonie pulmonaire induite par médicament (amphétamines) <= maladiepulmonaire interstitielle >=, une hypertension artérielle apparaissant avec le VIH, une hypertension pulmonaire thromboembolique, une hypertension pulmonaire chez des enfants et des nouveau-nés, une hypertension pulmonaire induite par hypoxie atmosphérique (mal de l'altitude), MPOC, un emphysème, un asthme chronique, une hypertonie pulmonaire induite par la mucoviscidose, une insuffisance cardiaque droite, une insuffisance cardiaque gauche, une insuffisance globale, une hypertension artérielle systolique isolée (<= ISH >=) et une rigidification des vaisseaux sanguins, notamment des vaisseaux sanguins artériels. Cette invention concerne aussi la combinaison d'inhibiteurs de PDE 5, en particulier de dérivés d'imidazotriazinone 2-phényl-substitués connus avec d'autres produits thérapeutiques pour les indications susmentionnées.

Affiliated with

Also associated with

Rating

Uses of 2-phenyl-substituted imidazotriazinone derivatives... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Uses of 2-phenyl-substituted imidazotriazinone derivatives..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Uses of 2-phenyl-substituted imidazotriazinone derivatives... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1362085